ритуксимабфолликулярная лимфомаполихимиотерапияиммунохимиотерапияrituximabfollicular lymphomapolychemotherapyimmunochemotherapy1.Singh V., Gupta D., Almasan A. Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. J Cancer Sci Ther 2015; 7(11): 347-58. DOI: 10.4172/1948-5956.1000373. PMID: 27413424. PMCID: PMC4939752.2.Pfreundschuh M., Trumper L., Osterborg A. et al. MabThera International Trial, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet. Oncology 2006; 7(5): 379-91. DOI: 10.1016/S1470-2045(06)70664-7. PMID: 16648042.3.McLaughlin P., Grillo Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8): 2825-33. DOI: 10.1200/jco.1998.16.8.2825. PMID: 9704735.4.Davis T.A., White C.A., Grillo-López A.J. et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17(6): 1851-7. DOI: 10.1200/jco.1999.17.6.1851. PMID: 10561225.5.Foran J.M., Gupta R.K., Cunningham D. et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109(1): 81-8. PMID: 10848785.6.Hainsworth J.D., Litchy S., Shaffer D.W. et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23(6): 1088-95. DOI: 10.1200/JCO.2005.12.191. PMID: 15657401.7.Hiddemann W., Kneba M., Dreyling M. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106(12): 3725-32. DOI: 10.1182/blood-2005-01-0016. PMID: 16123223.8.Herold M., Haas A., Srock S. et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25(15): 1986-92. DOI: 10.1200/JCO.2006.06.4618. PMID: 17420513.9.Marcus R., Imrie K., Solal-Celigny P. et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26(28): 4579-86. DOI: 10.1200/JCO.2007.13.5376. PMID: 18662969.10.Salles G., Mounier N., De Guibert S. et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112(13): 4824-31. DOI: 10.1182/blood-2008-04-153189. PMID: 18799723.11.Swerdlow S.H., Campo E., Harris N.L. et al. (Eds.) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, 2008.12.Cheson B.D., Horning S.J., Coiffier B. et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17(4): 1244. DOI: 10.1200/jco.1999.17.4.1244. PMID: 10561185.13.Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95. DOI: 10.1200/jco.1998.16.8.2780. PMID: 9704731.14.Horning S.J., Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311(23): 1471-75. DOI: 10.1056/NEJM198412063112303. PMID: 6548796.15.Friedberg J.W., Taylor M.D., Cerhan J.R. et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27(8): 1202-08. DOI: 10.1200/JCO.2008.18.1495. PMID: 19204203. PMCID: PMC2738614.16.Marcus R., Imrie K., Belch A. et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105(4): 1417-23. DOI: 10.1182/blood-2004-08-3175. PMID: 15494430.17.Forstpointner R., Dreyling M., Repp R. et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone [FCM] significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104(10): 3064-71. DOI: 10.1182/blood-2004-04-1323. PMID: 15284112.18.Murakami S., Kato H., Higuchi Y. et al. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. J Ann Hematol 2016; 95(8): 1259-69. DOI: 10.1007/s00277-016-2690-2. PMID: 27220639.19.Rummel M.J., Niederle N., Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381(9873): 1203-10. DOI: 10.1016/S0140-6736(12)61763-2. PMID: 23433739.20.Salles G., Seymour J.F., Offner F. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377 (9759): 42-51. DOI: 10.1016/S0140-6736(10)62175-7. PMID: 21176949.21.Fisher R.I., LeBlanc M., Press O.W. et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23(33): 8447-52. DOI: 10.1200/JCO.2005.03.1674. PMID: 16230674.22.Dave S.S., Wright G., Tan B. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-69. DOI: 10.1056/NEJMoa041869. PMID: 15548776.